A marker for the prognosis of CLL.
May be a key element in the pathogenesis of CLL.
An independent negative marker for CLL.
A transmembrane glycoprotein expressed on the surface of hematopoietic cells, and overexpressed on multiple myeloma cells.
CD38 is a transmembrane glycoprotein expressed on lymphoid and myeloma cells, and acts as the receptor for the transduction of activation signals and serves as a enzyme that catalyzes the production of nucleotides involved in calcium signaling.
In excellent therapeutic target in myeloma as it is expressed with relatively high surface density on abnormal plasma cells, whereas expression is lower on normal myeloid and lymphoid cells.
Involved in the delivery of growth and survival signals to neoplastic cells.
Percentage of CD38 cells in peripheral blood fluctuates widely being altered by the stage of CLL, and exposure to therapy.
CD38 positive cells express markers for cell prolferation such as Ki-67 and have shorter telomeres.
A transmembrane protein expressed abundantly on malignant plasma cells.